Category Research

CytoAgents

CytoAgents Completes Cohort 1 Dose-Escalation in Phase 1B Clinical Trial for Cytokine Release Syndrome Research

CytoAgents Completes Cohort 1 Dose-Escalation in Phase 1B Clinical Trial for Cytokine Release Syndrome Research CytoAgents Inc., a clinical-stage biotechnology company at the forefront of developing therapies for immune-mediated disorders, has announced a significant milestone in its ongoing Phase 1b/2a…

Read MoreCytoAgents Completes Cohort 1 Dose-Escalation in Phase 1B Clinical Trial for Cytokine Release Syndrome Research
Debiopharm

Debiopharm and Oncodesign Services Partner to Advance Radiopharmaceuticals in Preclinical Research

Debiopharm and Oncodesign Services Partner to Advance Radiopharmaceuticals in Preclinical Research Debiopharm Research & Manufacturing S.A. (Debiopharm), a privately held, Swiss-based global biopharmaceutical company committed to advancing the treatment landscape for cancer and infectious diseases, has announced a strategic licensing…

Read MoreDebiopharm and Oncodesign Services Partner to Advance Radiopharmaceuticals in Preclinical Research
Novocure

Novocure to Present Late-Breaking Phase 3 PANOVA-3 Data for TTFields in Pancreatic Cancer at ASCO 2025

Novocure to Present Late-Breaking Phase 3 PANOVA-3 Data for TTFields in Pancreatic Cancer at ASCO 2025 Novocure, a global leader in innovative cancer treatments, has announced that it will present additional data from its pivotal Phase 3 PANOVA-3 trial of…

Read MoreNovocure to Present Late-Breaking Phase 3 PANOVA-3 Data for TTFields in Pancreatic Cancer at ASCO 2025
Biotech

Metro International Biotech Begins Phase 1a Trial of NAD Booster MIB-725

Metro International Biotech Begins Phase 1a Trial of NAD Booster MIB-725 Metro International Biotech, LLC (MetroBiotech), a pioneering company in the development of next-generation therapies for age-associated diseases, has officially launched its first-in-human clinical trial for MIB-725, a novel investigational…

Read MoreMetro International Biotech Begins Phase 1a Trial of NAD Booster MIB-725
Glycomine

Glycomine Raises $115M Series C to Advance GLM101 into Phase 2b Trial for PMM2-CDG

Glycomine Raises $115M Series C to Advance GLM101 into Phase 2b Trial for PMM2-CDG Glycomine, Inc., a clinical-stage biotechnology company dedicated to developing life-changing therapies for patients suffering from orphan and underserved diseases, has announced the successful closure of a…

Read MoreGlycomine Raises $115M Series C to Advance GLM101 into Phase 2b Trial for PMM2-CDG
Octave

Octave Bioscience’s MSDA Test Demonstrates Clinically Actionable Insights for Improved MS Care Decisions

Octave Bioscience’s MSDA Test Demonstrates Clinically Actionable Insights for Improved MS Care Decisions In a significant advancement for the field of neurodegenerative disease management, Octave Bioscience, Inc., a precision care company focused on transforming how multiple sclerosis (MS) and other…

Read MoreOctave Bioscience’s MSDA Test Demonstrates Clinically Actionable Insights for Improved MS Care Decisions
Eyestem

Eyestem’s Eyecyte-RPE™ Demonstrates Vision Preservation in Geographic Atrophy Clinical Trial

Eyestem’s Eyecyte-RPE™ Demonstrates Vision Preservation in Geographic Atrophy Clinical Trial Bangalore-based biotech firm Eyestem Research has reported highly encouraging results from its Phase 1 clinical trial evaluating Eyecyte-RPE™, a novel investigational cell therapy aimed at treating geographic atrophy (GA) secondary…

Read MoreEyestem’s Eyecyte-RPE™ Demonstrates Vision Preservation in Geographic Atrophy Clinical Trial